Document is current

Article History

Received: 13 December 2019

Accepted: 21 January 2020

First Online: 10 February 2020

Ethics approval and consent to participate

: The APRICOT trial is being conducted in compliance with the principles of the Declaration of Helsinki (1996), the principles of GCP and in accordance with all applicable regulatory requirements. Ethical approval was granted from the London Dulwich Research Ethics Committee (REC), (16/LO/0436). The protocol and study has also been approved by the Health Research Authority (HRA) (Ref: 162093) and the Medicines and Healthcare products Regulatory Agency (MHRA) for Clinical Trial Authorisation (Ref: 11387/0026/001). Patients receive an information sheet and provide written informed consent prior to participating in study specific procedures.

: Not applicable

: CS declares departmental research funding from AbbVie, GSK, Pfizer, Novartis, Regeneron, and Roche. CS is a PI on consortia (BIOMAP and PSORT ) which have a number of industry partners. HJL declares funding from SOBI to support a nurse post in systemic autoinflammatory diseases. FC declares having received funding from Boehringer-Ingelheim and AnaptysBio. DAB declares honoraria for lectures, research or advisory boards from Abbvie, Almirall, Boehringer Ingelheim, Celgene, Janssen, Lilly, Novartis and UCB pharma. CEWG declares AbbVie (AD Board), Almirall (Consultant), BMS (Speaker), Galderma (AD Board), Janssen (Consultant/Speaker), LEO (Speaker), Lilly (AD Board/speaker), Novartis (AD Board/Speaker), Pfizer (AD Board), Samsung Bioepis (Consultant), Sandoz (AD Board), CG Skin (Stockholder), SynDermix (Consultant), UCB Pharma (AD Board), Walgreens Boots Alliance (AD Board/Speaker) and Celgene (AD Board/Speaker). No competing interests are known for the other authors.